FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Shan Man

Research Profile

Living Beings

Procedures

Anatomy

Chemicals & Drugs

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Christina Hackl; Shan Man; Chloe Milsom; Ping Xu; Giulio Francia; Robert S Kerbel
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Giulio Francia; Christina Hackl; Kae Hashimoto; Shan Man; Yuval Shaked; Julie Stewart; John Sun; Mark Uhlik; Ping Xu; Melissa Yin; Carolyn Cesta; Anne H Dantzig; F Stuart Foster; Robert S Kerbel
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Shan Man (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Christina Hackl; Shan Man; Chloe Milsom; Ping Xu; Giulio Francia; Robert S Kerbel
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
Gut 2013;62(2):259-71.
2012: Giulio Francia; Christina Hackl; Kae Hashimoto; Shan Man; Yuval Shaked; Julie Stewart; John Sun; Mark Uhlik; Ping Xu; Melissa Yin; Carolyn Cesta; Anne H Dantzig; F Stuart Foster; Robert S Kerbel
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Molecular cancer therapeutics 2012;11(3):680-9.
2011: Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Mouse models of advanced spontaneous metastasis for experimental therapeutics.
Nature reviews. Cancer 2011;11(2):135-41.
2011: Urban Emmenegger; Giulio Francia; Annabelle Chow; Yuval Shaked; Andrew Kouri; Shan Man; Robert S Kerbel
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
Neoplasia (New York, N.Y.) 2011;13(1):40-8.
2010: Terence C Tang; Shan Man; Ping Xu; Giulio Francia; Kae Hashimoto; Urban Emmenegger; Robert S Kerbel
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Neoplasia (New York, N.Y.) 2010;12(11):928-40.
2010: Terence C Tang; Shan Man; Christina Lee; Ping Xu; Robert S Kerbel
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Neoplasia (New York, N.Y.) 2010;12(3):264-74.
2009: Giulio Francia; Shan Man; Chyan-Jang Lee; Christina Lee; Ping Xu; Miriam Mossoba; Urban Emmenegger; Jeffrey A Medin; Robert S Kerbel
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(20):6358-66.
2009: Chris Folkins; Yuval Shaked; Shan Man; Terence Tang; Christina Lee; Zhenping Zhu; Robert M Hoffman; Robert S Kerbel
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1.
Cancer research 2009;69(18):7243-51.
2009: William Cruz-Munoz; Shan Man; Robert S Kerbel
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(15):4867-74.
2009: Anthony J Mutsaers; Giulio Francia; Shan Man; Christina Lee; John M L Ebos; Yan Wu; Larry Witte; Scott Berry; Malcolm Moore; Robert S Kerbel
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2397-405.
2008: Giulio Francia; Urban Emmenegger; Christina Lee; Yuval Shaked; Christopher Folkins; Miriam Mossoba; Jeffrey A Medin; Shan Man; Zhenping Zhu; Larry Witte; Robert S Kerbel
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines.
Molecular cancer therapeutics 2008;7(10):3452-9.
2008: Yuval Shaked; Erik Henke; Jeanine M L Roodhart; Patrizia Mancuso; Marlies H G Langenberg; Marco Colleoni; Laura G Daenen; Shan Man; Ping Xu; Urban Emmenegger; Terence Tang; Zhenping Zhu; Larry Witte; Robert M Strieter; Francesco Bertolini; Emile E Voest; Robert Benezra; Robert S Kerbel
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Cancer cell 2008;14(3):263-73.
2008: William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
Cancer research 2008;68(12):4500-5.
2007: Shan Man; Raquel Munoz; Robert S Kerbel
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Cancer metastasis reviews 2007;26(3-4):737-47.
2007: Urban Emmenegger; Yuval Shaked; Shan Man; Guido Bocci; Ivan Spasojevic; Giulio Francia; Andrew Kouri; Robert Coke; William Cruz-Munoz; Susan M Ludeman; O Michael Colvin; Robert S Kerbel
Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
Molecular cancer therapeutics 2007;6(8):2280-9.
2007: Chris Folkins; Shan Man; Ping Xu; Yuval Shaked; Daniel J Hicklin; Robert S Kerbel
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Cancer research 2007;67(8):3560-4.
2006: Yuval Shaked; Alessia Ciarrocchi; Marcela Franco; Christina Lee; Shan Man; Alison M Cheung; Daniel J Hicklin; David Chaplin; F Stuart Foster; Robert Benezra; Robert S Kerbel
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
Science (New York, N.Y.) 2006;313(5794):1785-7.
2006: Rena Buckstein; Robert S Kerbel; Yuval Shaked; Rakesh Nayar; Cindy Foden; Ruth Turner; Christina Lee; Diane Taylor; Liying Zhang; Shan Man; Sylvain Baruchel; Diana Stempak; Francesco Bertolini; Michael Crump
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5190-8.
2006: Sylvia S W Ng; Alex Sparreboom; Yuval Shaked; Christina Lee; Shan Man; Neil Desai; Patrick Soon-Shiong; William D Figg; Robert S Kerbel
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4331-8.
2006: Marcela Franco; Shan Man; Limor Chen; Urban Emmenegger; Yuval Shaked; Alison M Cheung; Allison S Brown; Daniel J Hicklin; F Stuart Foster; Robert S Kerbel
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.
Cancer research 2006;66(7):3639-48.
2006: Raquel Munoz; Shan Man; Yuval Shaked; Christina Lee; John Wong; Giulio Francia; Robert S Kerbel
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Cancer research 2006;66(7):3386-91.
2006: Jeanne M du Manoir; Giulio Francia; Shan Man; Miriam Mossoba; Jeffrey A Medin; Alicia Viloria-Petit; Daniel J Hicklin; Urban Emmenegger; Robert S Kerbel
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):904-16.
2006: Urban Emmenegger; Gerard Morton; Giulio Francia; Yuval Shaked; Marcela Franco; Adina Weinerman; Shan Man; Robert S Kerbel
Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Cancer research 2006;66(3):1664-74.
2005: Raquel Munoz; Yuval Shaked; Francesco Bertolini; Urban Emmenegger; Shan Man; Robert S Kerbel
Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
Breast (Edinburgh, Scotland) 2005;14(6):466-79.
2005: Yuval Shaked; Guido Bocci; Raquel Munoz; Shan Man; John M L Ebos; Daniel J Hicklin; Francesco Bertolini; Robert D'Amato; Robert S Kerbel
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.
Current cancer drug targets 2005;5(7):551-9.
2005: Yuval Shaked; Urban Emmenegger; Shan Man; Dave Cervi; Francesco Bertolini; Yaacov Ben David; Robert S Kerbel
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
Blood 2005;106(9):3058-61.
2005: Giulio Francia; Shane K Green; Guido Bocci; Shan Man; Urban Emmenegger; John M L Ebos; Adina Weinerman; Yuval Shaked; Robert S Kerbel
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.
Molecular cancer therapeutics 2005;4(10):1484-94.
2005: Yuval Shaked; Urban Emmenegger; Giulio Francia; Limor Chen; Christina Lee; Shan Man; Armen Paraghamian; Yaacov Ben David; Robert S Kerbel
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Cancer research 2005;65(16):7045-51.
2005: Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
Cancer cell 2005;7(1):101-11.
2004: Guido Bocci; Shan Man; Shane K Green; Giulio Francia; John M L Ebos; Jeanne M du Manoir; Adina Weinerman; Urban Emmenegger; Li Ma; Philip Thorpe; Andrew Davidoff; James Huber; Daniel J Hicklin; Robert S Kerbel
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
Cancer research 2004;64(18):6616-25.
2004: Giulio Francia; Shan Man; Beverly Teicher; Luigi Grasso; Robert S Kerbel
Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.
Molecular and cellular biology 2004;24(15):6837-49.
2004: John M L Ebos; Guido Bocci; Shan Man; Philip E Thorpe; Daniel J Hicklin; Danielle Zhou; Xiaohong Jia; Robert S Kerbel
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
Molecular cancer research : MCR 2004;2(6):315-26.
2004: Urban Emmenegger; Shan Man; Yuval Shaked; Giulio Francia; John Wong; Daniel J Hicklin; Robert S Kerbel
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
Cancer research 2004;64(11):3994-4000.
2003: Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(22):12917-22.
2002: Shan Man; Guido Bocci; Giulio Francia; Shane K Green; Serge Jothy; Douglas Hanahan; Peter Bohlen; Daniel J Hicklin; Gabriele Bergers; Robert S Kerbel
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Cancer research 2002;62(10):2731-5.
2002: Giannoula Klement; Ping Huang; Barbara Mayer; Shane K Green; Shan Man; Peter Bohlen; Daniel J Hicklin; Robert S Kerbel
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):221-32.
2001: B Mayer; Giannoula Klement; M Kaneko; Shan Man; Serge Jothy; Janusz Rak; Robert S Kerbel
Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas.
Gastroenterology 2001;121(4):839-52.
2001: Robert S Kerbel; J Yu; Jennifer Tran; Shan Man; Alicia Viloria-Petit; Giannoula Klement; Brenda L Coomber; Janusz Rak
Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.
Cancer metastasis reviews 2001;20(1-2):79-86.
2000: Giannoula Klement; Sylvain Baruchel; Janusz Rak; Shan Man; K Clark; Daniel J Hicklin; Peter Bohlen; Robert S Kerbel
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
The Journal of clinical investigation 2000;105(8):R15-24.